ALK and non-small cell lung carcinoma: NSCLC tumors feature a similar poor prognosis, except for those variants amenable to specific therapies directed to mutated epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and other kinases [4,5].